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BACKGROUND: The angiotensin-converting enzyme inhibitors (ACEIs) have become the forefront of heart failure treatment for more than 
a decade. Currently, angiotensin receptor blockers (ARBs) 
are thought to have similar effectiveness. This study 
aimed to compare the impact of captopril, one of ACEI, 
and valsartan, one of ARB, on clinical presentation and 
echocardiographic, electrocardiographic, and chest x-ray 
improvement in patients with left-to-right shunt congenital 
heart diseases.
METHODS: This study used a double-blind randomized 
controlled  trial  of captopril and valsatran to  children  with 
left-to-right  shunt congenital heart diseases who suffer from 
heart failure in the Dr. Soetomo General Hospital, Surabaya, 
Indonesia. Pediatric heart failure scores, echocardiography, 
electrocardiography (ECG), and chest photographs were 
examined at the beginning  of the  study  and  after  30  days 
of  treatment.
RESULTS: A decrease in pediatric heart failure scores 
were showed after the administration of ACEI (7.06±2.04 
vs. 4.75±2.43; p<0.0001; 95% CI: −2.98 - 1.65); ARB 
(6.81±2.25 vs. 3.94±1.98; p<0.0001; 95% CI: −3.76 to 
1.98). The echocardiography examination, an increase in left 
ventricular end-diastolic volume (LVEDV), left ventricular 
ejection fraction (LVEF), % fractional shortening (FS), 
and left ventricular (LV) dimension occurred after the 
administration of ACEI and ARB. The values also didn’t 
significantly differrent between the two groups. The ECG 
evaluation showed a decrease in heart rate frequency after 
the administration of ACEI (117.75±14.67 vs. 109.63±17.59; 
p=0.039; 95% CI: −15.78 to −0.46) and ARB (117.10±21.86 
vs.108.6±20.66; p=0.006; 95% CI: −14.17 to −2.83).
CONCLUSION: ARB showed better outcome in clinical 
condition, echocardiography, ECG, and chest radiographs.
KEYWORDS: captopril, valsartan, heart failure, congenital 
heart disease, left to right shunt
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Abstract
Introduction
Congenital heart disease (CHD) is a disease that leads to 
heart structure and/or circulation function abnormalities 
that can be observed immediately after birth or later in 
life. Most of the cases are complex and require adequate 
treatment as early as possible.(1) The incidence of CHD in 
Indonesia is quite common. Nevertheless, proper facilities 
and infrastructure, including diagnostic, therapeutic, 
and operative. for CHD treatment are still inadequate in 
Indonesia.(2)
 CHD prevalence is estimated to be 6 to 10 per 1.000 
live births, with an average of 8 out of 1.000 live births. 
Approximately one-third of them will show symptoms that 
vary from mild to severe, which may emerge in the first 
weeks of life.(3) If these symptoms are not detected earlier 
and not treated properly, 50% of deaths will occur in the 
first month of life. One of the most common complications 
that often occur in CHD is heart failure. Heart failure is the 
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heart’s inability as a blood pump to adequately meet the 
body’s metabolic needs. This condition might be caused by 
primary heart muscle disorders or excessive cardiac burden 
or a combination of both.(1)
 The current heart failure therapy for CHD is still 
unsatisfactory. Many trials in novel drugs have been 
conducted to treat heart failure. Management of heart failure 
in children is generally based on clinical experience and 
application of findings in trials involving adults, supported 
by limited literature and research in the pediatric population. 
Nevertheless, the clinical outcomes in children using drugs 
that have been proven to be beneficial in adults result in 
equally beneficial outcomes.(4) Angiotensin-converting 
enzyme inhibitors (ACEIs) have become the forefront of 
heart failure treatment for more than a decade. The most 
commonly used ACEIs are captopril and enalapril. Currently, 
angiotensin receptor blockers (ARBs) are thought to have 
similar effectiveness as ACEIs in treating hypertension, 
congestive heart failure, and chronic kidney disease.(5) 
Most of ARB research in heart failure was conducted in 
adults.(6) There is no similar study that is conducted in 
children with left-to-right shunt CHD who suffer from heart 
failure in Indonesia. 
 The aim of this study is to compare the clinical, 
echocardiographic, electrocardiographic, and chest 
radiograph changes before and after captopril administration 
and before and after valsartan administration on children 
with left-to-right CHD who have heart failure.
Methods
Study Design
The study was approved by the ethics commission of Dr. 
Soetomo General Hospital, Surabaya, Indonesia (No. 38/
Panke.KKE/02/II/2010). This study used randomized 
controlled trial (RCT) design in a double-blind study. 
The population of this study included the inpatients and 
outpatients of the Pediatric Cardiology Division of the 
Pediatric Department of Dr. Soetomo General Hospital, 
Surabaya, with left-to-right shunt CHD (ventricular septum 
defect (VSD), atrial septum defect (ASD), patent ductus 
arteriosus (PDA)) who met the criteria of heart failure using 
pediatric heart failure score. 
Pediatric Heart Failure Scoring
Pediatric heart failure score consist of diaphoresis, tachipnea, 
breathing, respiratory rate, heart rate, and liver edge with 
criteria : No congestive heart failure (CHF): 0–2 points; 
Mild CHF: 3–6 points; Moderate CHF: 7–9 points; Severe 
CHF: 10–12 points.(7) The inclusion criteria in this study 
were children aged 1 to 16 years old who met the criteria 
of heart failure according to the pediatric heart failure 
scores with >2 score. The exclusion criteria were patients 
with surgery planned within one month, an impaired kidney 
function (GFR <90 mL/minute/1.73 m2), a serum potassium 
level >5.5 mEq/L. and a history of preceding heart failure 
therapy (captopril, furosemide, digitalis). The subjects were 
randomly selected and then sorted into two groups: valsartan 
and captopril, with a minimal sample of 16 children in each 
group.
Clinical Examinations
Each research subject was examined for echocardiography, 
electrocardiography (ECG), and chest radiograph. 
Echocardiography was performed with digital color 
ultrasonography developed by GE Medical System to 
identify left ventricular end-diastolic volume (LVEDV), 
left ventricular ejection fraction (LVEF), % fractional 
shortening (FS), and left ventricular (LV) dimension by a 
consultant pediatric cardiologist. LVEDV is the final volume 
of left ventricular diastolic that is calculated based on the 
size of left ventricular internal diameter at end diastole 
(LVIDd), with a normal value <5.6 cm.(8) LVEF is the 
left ventricular ejection fraction that indicates heart pump 
function and is measured by the modified Simpson method 
([end-diastolic volume (EDV) - end-systolic volume (ESV)] 
/ EDV × 100%) with normal values between 56% and 78%.
(9) LV dimension is the distance between the two sides in 
the endocardium slightly below the bicuspid valve with a 
normal value based on body weight (lb). The %FS = [left 
ventricular diastolic dimension (LVDD) – left ventricular 
systolic dimension (LVSD)]/(LVDD) refers to the percent 
changes in the left ventricular diameter that occurs during 
systole or shortening of the fraction as an indicator of the 
efficiency of the left ventricular pump with normal values 
ranging from 28% to 44%.(8)
 An ECG was performed with the patient lying in 
a relaxed state, using a cardiofax ECG device that was 
interpreted by a consultant pediatric cardiologist. From the 
chest radiograph, a chest x-ray/CTR: cardiothoracic ratio 
(CTR) measurement was made using a ruler.
 The sorting and distribution of drugs were carried out 
by the pharmaceutical department in a blind manner, and 
the drugs were given three times a day after meals for four 
weeks. Group 1 was given captopril at a dose of 0.3 mg/
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kg body weight (BW) three times daily. Group 2 was given 
valsartan with a dose of 1.3 mg/kg BW once a day in the 
morning after breakfast, and two other drugs in powder 
form containing placebo were given during the day and 
night. The drugs were given orally by doctors or paramedics 
for  inpatients  and  with the help of  their  parents  for  the 
outpatients.  To monitor the patients’ compliance in taking 
the medicine, a checklist  of  drug  administration  was 
used  and  filled  by the patients’  parents  or  the  patients 
themselves.  If the drug was not taken, then the reason must 
be mentioned. All  patients  also  received  heart  failure 
therapy,  including  diuretics (spironolactone) at a dose of 
1 mg/kg once a day. After 30 days of drug administration, 
an evaluation of pediatric heart failure scores, ECG, 
echocardiography, chest radiograph, and adverse reactions 
was conducted.
Statistical Analysis 
The collected data were analyzed using paired t-test to 
compare pre and post data, and Mann-Whitney test to 
compare valsartan vs. captopril, with significance level 
p<0.05. The data analysis was done using SPSS (IBM, New 
York, USA).  
Results
During four months, from July to October 2010, 32 children 
were included as subjects and randomly divided into two 
groups, the captopril gruop and valsartan group. Each group 
consisted of 16 children, and their characteristics can be 
found in Table 1.
 In this study, there was a decrease in pediatric heart 
failure  scores  after  the  administration  of  captopril 
(7.06±2.04  vs. 4.75±2.43; p< 0.0001; 95%CI: −2.98 to 
1.65) (Table 2). There was also a decrease in pediatric 
heart failure scores after the administration of valsartan 
(6.81±2.25 vs. 3.94±1.98; p< 0.0001; 95%CI: −3.76 to 1.98) 
(Table 3).
 There was no differences in LVEDV, LVEF, % FS, 
and LV dimension after the administration of captopril and 
valsartan (p>0.05). The ECG evaluation showed a decrease 
in heart rate frequency after the administration of captopril 
and valsartan (p<0.05) (Table 2 and Table 3).
 There were a no differences in pediatric heart failure 
scores, echocardiography, ECG, and CTR between captopril 
and valsartan group (p>0.05) (Table 4.).
Characteristics Group 1 (Captopril)
Group 2 
(Valsartan)
p -value
Age (months), Mean±SD 73.4±55.8 55.3±29.6 0.263
Weight (kg), Mean±SD 17.41±11.4 14.9±7.8 0.462
Sex, n
       Male 6 6
       Female 10 10
Nutritional status, n(%)
Over nourished 1 (6.3) 0
Normal 4 (25) 6 (37.5)
Malnourished 10 (62.5) 8 (50.0)
Severely malnourished 1 (6.3) 2 (12.5)
Left-to-right shunt defect, n(%)
VSD 7 (43.8) 6 (37.5)
ASD 5 (31.2) 3 (18.7)
PDA 4 (25.0) 7 (43.8)
Temperature (Celsius), Mean±SD 36.8±0.2 36.9±0.7 0.511
1.000
0.966
0.498
Table 1. Subjects' characteristics before the drug administration.
SD: standar deviation; VSD: ventricular septum defect;  ASD: atrial septum defect; PDA: patent ductus 
arteriosus.
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Pre
(Mean±SD)
Post
(Mean±SD)
Pediatric heart failure score 7.06±2.04 4.75±2.43 0.000 −2.98 - (−1.65)
Echocardiography
     LVEDV (g/mL) 44.58±20.05 46.12±23.63 0.689 −6.48 - 9.56
     LVEF (%) 74.54±3.84 75.55±4.66 0.423 −1.60 - 3.62
     FS (%) 41.31±2.80 42.21±5.17 0.562 −2.35 - 4.17
     LV dimension (g/m2) 3.29±0.58 3.30±0.71 0.961 −0.23 - 0.24
ECG
     Heart rate (x/min) 117.75±14.67 109.63±17.59 0.039 −15.78 - (−0.46)
     R amplitude in V1 lead (mV) 7.06±6.69 7.13±5.16 0.962 −2.73 - 2.83
     R amplitude in V6 lead (mV) 15.50±6.02 13.63±7.66 0.373 −6.23 - 2.48
     S amplitude in V1 lead (mV) 6.38±5.12 6.56±6.14 0.885 −2.52 - 2.89
     S amplitude in V6 lead (mV) 5.03±7.15 3.59±4.88 0.095 −3.16 - 0.28
CTR (%) 60.92±5.64 59.61±5.16 0.062 −2.70 - 0.07
CI 95%Variables
Group 1 (Captopril)
p -value
Pre
(Mean±SD)
Post
(Mean±SD)
Pediatric heart failure score 6.81±2.25 3.94±1.98 0.000 −3.76 - (−1.98)
Echocardiography
     LVEDV (g/mL) 58.74±29.77 61.32±35.11 0.721 −12.51 - 17.67
     LVEF (%) 74.26±3.86 73.28±4.10 0.494 −3.97 - 2.00
     FS (%) 41.53±4.29 41.11±3.48 0.761 −3.24 - 2.42
     LV dimension (g/m2) 3.64±0.72 3.65±0.78 0.919 −0.28 - 0.31
ECG
     Heart rate (x/min) 117.10±21.86 108.60±20.66 0.006 −14.17 - (−2.83)
     R amplitude in V1 lead (mV) 9.13±4.96 7.69±2.91 0.169 −3.56 - 0.68
     R amplitude in V6 lead (mV) 16.60±6.62 14.38±5.87 0.125 −5.19 - 0.69
     S amplitude in V1 lead (mV) 10.06±6.78 7.31±5.99 0.009 −4.69 - (−0.81)
     S amplitude in V6 lead (mV) 3.81±3.06 3.53±2.70 0.660 −1.61 - 1.05
CTR (%) 59.74±4.72 57.19±5.14 0.000 −3.87 - 1.23
Variables
Group 2 (Valsartan)
p -value CI 95%
Table 2. Changes of clinical manifestation, echocardiography, ECG, and CTR in the captopril group.
SD: standar deviation; CI: confidence interval; LVEDV: left ventricular end-diastolic volume; LVEF: left 
ventricular ejection fraction; FS: fractional shortening; LV: left ventricular; ECG: electrocardiography;  CTR: 
cardiothoracic ratio.
SD: standar deviation; CI: confidence interval; LVEDV: left ventricular end-diastolic volume; LVEF: left 
ventricular ejection fraction; FS: fractional shortening; LV: left ventricular; ECG: electrocardiography;  CTR: 
cardiothoracic ratio.
Table 3. Changes of clinical manifestation, echocardiography, ECG, and CTR in the valsatran group.
Discussion
In left-to-right shunt CHD with medium to large defect 
size, a volume overload occurs. The body will compensate 
as an adaptive response to a decrease of heart function that 
is marked by various adaptive responses in the form of 
myocardial dilatation and hypertrophy; peripheral vascular 
vasoconstriction and activation of the renin-angiotensin-
aldosterone system.(10) The effects of angiotensin II (A II) 
mediated by angiotensin II type 1 (AT1) receptors include 
vasoconstriction, salt retention, and growth changes in 
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Variables Group 1 (Captopril)Mean±SD
Group 2 (Valsartan)
Mean±SD p -value
Pediatric heart failure score −2.31±1.25 −2.87±1.66 0.289
Echocardiography
LVEDV (g/mL) 1.53±15.06 2.57±28.33 0.898
LVEF (%) 1.01±4.90 −0.98±5.61 0.293
FS (%) 0.91±6.12 −0.41±5.31 0.520
LV dimension (g/m2) 0.01±0.45 0.01±0.49 0.961
ECG
Heart rate (x/min) −8.12±14.37 −8.50±10.63 0.934
R amplitude in V1 lead (mV) 0.062±5.20 −1.43±3.98 0.367
R amplitude in V6 lead (mV) −1.87±8.17 −2.25±5.53 0.880
S amplitude in V1 lead (mV) 0.187±5.08 −2.75±3.64 0.070
S amplitude in V6 lead (mV) −1.43±3.22 −0.28±2.50 0.267
CTR (%) −1.31±2.60 −2.55±2.47 0.178
Table 4. Changes of clinical manifestation, echocardiography, ECG, and CTR between the 
captopril and valsartan groups.
SD: standar deviation; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular 
ejection fraction; FS: fractional shortening; LV: left ventricular; ECG: electrocardiography;  CTR: 
cardiothoracic ratio.
myocytes and cause heart remodelling.(11) Measurement 
and monitoring of left ventricular remodeling include the 
size and shape of the heart that can be assessed from chest 
radiographs through CTR size, from ECG through left 
ventricular hypertrophy finding, from echocardiography 
through measured LV dimension. LVEDV, FS, and ejection 
fraction.(12)
 Various studies have been conducted to compare 
the use of ARB with ACEI. These studies were mostly 
conducted in adult patients and rarely in children. Losartan 
Heart Failure Survival Study, which was conducted in 200, 
recommends the use of ARB as an alternative therapy in 
patients who cannot tolerate the use of ACEI.(13)
 Previous study reported that the addition of valsartan 
in heart failure patients who received standard therapy for an 
average of 23 months significantly improved the New York 
Heart Association (NYHA) functional class, left ventricular 
remodeling, and symptoms and signs of heart failure.(14) 
The administration of captopril and valsartan for six months 
in congestive heart failure patients improved heart failure 
symptoms as measured by increased NYHA class that was 
better than captopril administration alone.(15)
 ARB blocks the effects of A II by inhibiting the 
AT1 receptor, and it is reported to affect LV hypertrophy 
regression and cardiac remodeling in hypertension and 
heart failure.(16) Valsartan works specifically by blocking 
the interaction of A II with AT1 receptors. An increase in A 
II is known to increase the stimulation of beneficial effects 
mediated by the AT2 receptor through vasodilation and 
antifibrinolytic mechanisms.(17)
 In the present study, the results of the statistical analysis 
showed a significant change in pediatric heart failure scores 
(p<0.0001) before and after captopril administration, as 
well as before and after valsartan administration, but the 
results were not statistically significant when compared 
with the two treatment groups (Table 4). These results 
were in accordance with Valsartan Heart Failure Trial 
(Val-HeFT) and Randomized Evaluation of Strategies for 
Left Ventricular Dysfunction (RESOLVD) studies that 
reported no significant differences in clinical scores after 
the administration of ACEI and ARB.(14) Nevertheless, in 
the present study, the average of pediatric heart failure score 
decrease appeared to be greater in the valsartan group than 
the captopril group. Therefore, the clinical improvement that 
occurred seemed to be better after valsartan administration.
LVEDV reflects structural remodeling and diastolic filling. 
LVEF derives from LV volume. Although heart rate and FS 
both affect ejection fraction, they are further affected by 
LVEDV because the change in stroke volume tends to be 
smaller than the change in LVEDV. Decreased LVEF was 
associated with a poor prognosis for heart failure. The FS 
is derived from a linear measurement that quantitatively 
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measures the function of ventricular contractility; therefore, 
it can be used as an indicator for the expansion of the 
structural remodeling of the ventricle.(14)
 Long-term therapy for approximately three to four 
years with effective ACE inhibitors did not only reduce 
the volume of overloaded LV but also LV hypertrophy 
(LV mass) in the heart of children with left ventricular 
volume overload (p=0.0007).(18) Valsartan affected the 
morbidity and mortality of patients with heart failure 
(p<0.001) by comparing ejection fraction, LV dimension, 
and neurohormonal plasma levels in a group that did not 
receive ACE therapy.(19)
 In the present study, there was less increase of LVEDV 
and LV dimension after captopril administration compared 
with valsartan (Table 4). This result was not in accordance 
with a previous study, in their preliminary study of heart 
muscle fibrosis and LV stiffness in the dog model with heart 
failure, reported a significant reduction in LVEDV after 
captopril and valsartan administration for four weeks.(20)
 In the present study, an increase in LVEF occurred 
after captopril administration even though the results of the 
statistical analysis were not significant compared with the 
valsartan group (Table 4). There was a greater % FS increase 
after captopril administration than the valsartan group, even 
though the results were not statistically significant. 
 The ECG components that were evaluated were heart 
rate frequency and R and S wave amplitude parameters. In 
this study, a statistically significant decrease in heart rate 
frequency was observed in both groups, but the average 
heart rate decrease in the valsartan group was greater than 
that in the captopril group.
 A decrease in the R and S wave amplitudes at the 
V1 and V6 leads in the valsartan group was found, with 
a mean decrease in wave amplitude greater than that in 
the captopril group, although the statistical analysis did 
not show a significant difference except for the S wave 
amplitude parameters at the V1 leads. This result shows 
that in the valsartan group, there was a regression of LV 
hypertrophy that was marked by a decrease in the R wave 
amplitude at the V6 lead and the S wave amplitude at the 
V1 lead. Previous study compared the effects of losartan 
and valsartan on LV hypertrophy and LV function in 
patients with essential hypertension and concluded that a 
more significant LV hypertrophy regression occurred after 
valsartan administration for six months.(21)
 Measurement and monitoring of left ventricular 
remodeling include the size and shape of the heart that 
can be assessed from a chest radiograph through CTR. 
Cardiomegaly is assessed if CTR >50%. A significant 
decrease of CTR occurred in hypertensive patients with 
chronic peritoneal dialysis who received ARB compared 
with the control group for blood pressure variability and 
cardiovascular remodeling.(22) A decrease in CTR occurred 
after a combination of irbesartan with conventional therapy 
including ACEI in patients with heart failure.(23)
 In the present study, a decrease of CTR was found 
after captopril and valsartan administration (Table 2 and 
Table 3). The statistical analysis results showed a significant 
decrease of CTR in the valsartan group (Table 3), and the 
mean reduction of CTR in the valsartan group was greater 
than that in the captopril group (Table 4).
 A previous study reported that ARB is as effective 
as ACEI in reducing mortality and hospitalization due to 
heart failure.(24) In this study, evaluation after treatment 
concluded that valsartan might provide a better effect than 
captopril. In the valsartan group, the following were found: 
a decrease in pediatric heart failure score, a decrease in heart 
rate frequency, a decrease in the R wave amplitude at the 
V1 and V6 leads, a decrease in the S amplitude at the V1 
lead, and a greater CTR decrease and fewer side effects than 
the captopril group. In this study, the relative risk (RR) was 
0.857, which means that heart failure occurred 0.8 times in 
the valsartan group relative to the captopril group. With RR 
<1, it can be concluded that valsartan decreases the risk of 
heart failure. Absolute risk reduction (ARR)=0.125, which 
means that the average absolute difference in the incidence 
of heart failure is 0.125, with a positive ARR value 
indicating that valsartan is beneficial. Relative risk reduction 
(RRR)=14.3%, which shows that valsartan administration 
reduced heart failure by 14.3%.
 Valsartan with a half-life of six hours is given once a 
day, while captopril with a half-life of less than three hours 
is given two to three times a day. This condition shows 
that valsartan at a dose of 1.3 mg/kgBW once a day is safe 
enough to be given to a population of children with left-to-
right shunt who suffer from heart failure. Thus, valsartan is 
better than captopril. 
 Pharmacological failure associated with inadequate 
doses or the frequency of ACEI administration or the activity 
of non-ACE pathways remains unclear. Therefore, efforts 
to inhibit angiotensin more effectively by using valsartan 
appear to be more rational.(15)
 The limitation of this stuty are limited subjects and 
short period observation. A research with a longer period is 
needed to observe the efficacy of valsartan in the process of 
cardiac remodeling.
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Conclusion
Valsartan administration resulted in improved clinical, 
echocardiographic, ECG, and chest radiographs and fewer 
side effects (coughing) compared with captopril. Valsartan 
can be used as one of the drug choices besides captopril for 
the treatment of heart failure in children with left-to-right 
shunt CHD. 
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